Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HRS A-Fib Ablation Consensus Statement Offers Clinical Trial Advice

This article was originally published in The Gray Sheet

Executive Summary

A new expert 1consensus statement on ablation of atrial fibrillation, created by a Heart Rhythm Society task force, includes 21 specific recommendations for the design and conduct of clinical trials of AF ablation devices

You may also be interested in...



AF Ablation Attracts Stronger Support In Updated Clinical Guidelines

The growing use of catheter ablation to treat atrial fibrillation is supported by increasingly strong evidence, though the procedure should remain, for now, a second-line therapy to antiarrhythmic drugs, according to U.S. cardiology society guideline updates issued Dec. 20.

AF Ablation Attracts Stronger Support In Updated Clinical Guidelines

The growing use of catheter ablation to treat atrial fibrillation is supported by increasingly strong evidence, though the procedure should remain, for now, a second-line therapy to antiarrhythmic drugs, according to U.S. cardiology society guideline updates issued Dec. 20.

FDA, Cardiac Safety Research Consortium To Develop AF Ablation Registry

A consortium of academics, manufacturers and government agencies plans to launch a national atrial fibrillation ablation registry, based on input from a variety of stakeholders at a meeting April 27 and 28 at FDA's White Oak, Md., headquarters

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT024793

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel